- Home
- GDEV vs MLYS Comparison
GDEV vs MLYS Comparison
Compare GDEV & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GDEV
- MLYS
- Stock Information
- Founded
- GDEV 2009
- MLYS 2019
- Country
- GDEV Cyprus
- MLYS United States
- Employees
- GDEV N/A
- MLYS N/A
- Industry
- GDEV EDP Services
- MLYS Biotechnology: Pharmaceutical Preparations
- Sector
- GDEV Technology
- MLYS Health Care
- Exchange
- GDEV Nasdaq
- MLYS Nasdaq
- Market Cap
- GDEV 520.6M
- MLYS 590.3M
- IPO Year
- GDEV N/A
- MLYS 2023
- Fundamental
- Price
- GDEV $26.00
- MLYS $11.48
- Analyst Decision
- GDEV Buy
- MLYS Strong Buy
- Analyst Count
- GDEV 2
- MLYS 2
- Target Price
- GDEV $70.00
- MLYS $30.00
- AVG Volume (30 Days)
- GDEV 6.9K
- MLYS 229.8K
- Earning Date
- GDEV 11-14-2024
- MLYS 11-11-2024
- Dividend Yield
- GDEV N/A
- MLYS N/A
- EPS Growth
- GDEV N/A
- MLYS N/A
- EPS
- GDEV 2.48
- MLYS N/A
- Revenue
- GDEV $443,165,000.00
- MLYS N/A
- Revenue This Year
- GDEV N/A
- MLYS N/A
- Revenue Next Year
- GDEV $6.12
- MLYS N/A
- P/E Ratio
- GDEV $10.50
- MLYS N/A
- Revenue Growth
- GDEV N/A
- MLYS N/A
- 52 Week Low
- GDEV $19.00
- MLYS $5.85
- 52 Week High
- GDEV $42.76
- MLYS $16.91
- Technical
- Relative Strength Index (RSI)
- GDEV 39.77
- MLYS 35.00
- Support Level
- GDEV $24.30
- MLYS $13.70
- Resistance Level
- GDEV $32.60
- MLYS $15.04
- Average True Range (ATR)
- GDEV 2.94
- MLYS 0.89
- MACD
- GDEV -1.03
- MLYS -0.30
- Stochastic Oscillator
- GDEV 9.21
- MLYS 2.08
About GDEV GDEV Inc.
GDEV Inc is a gaming and entertainment holding company that oversees a portfolio of studios focused on developing and publishing live-service games across a range of platforms and genres. Its portfolio includes studios specializing in mobile, browser, and PC games, as well as captivating IPs spanning various genres.
About MLYS Mineralys Therapeutics Inc.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking three or more antihypertensive medications typically including a diuretic.